


# Technical Report No. 54-2

## Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

### Annex 1: Case Study Examples for Quality Risk Management in Packaging and Labeling

**PCMO**<sup>SM</sup>  
Paradigm Change in  
Manufacturing Operations<sup>SM</sup>



2013



# **PDA Task Force on Technical Report No. 54-2: Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations**

## **Annex 1: Case Study Examples for Quality Risk Management in Packaging and Labeling**

---

### **Authors**

---

**Ghada Haddad**, MBA, Chair Genentech/Merck

**Mike Boyson**, Millennium: The Takeda Oncology Company

**Boriana Cavicchia**, URS

**Mary Foster**, PharmD, Aphenia Pharma Solutions

**Mark Frankcom**, YellowScape Consulting

**Martin Hunter**, Amgen

**Bill Leung**, Genentech

**Liza Munda**, Genentech

**Mindy Pang**, Merck

**James Robinson**, Lachman Consultants

**David Thatcher**, Amgen

PDA would like to acknowledge the contributions of **Jeffrey Hartman** (Merck) and **Christopher Smalley** (Merck), who served as PDA Advisory Board subject-matter advisors to this technical report team.

**Disclaimer:** This technical report annex was developed as part of PDA's Paradigm Change in Manufacturing Operations (PCMO) project. The content and views expressed in this Technical Report are the result of a consensus achieved by the Task Force and are not necessarily views of the organizations they represent.

# **Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations**

## **Annex 1: Case Study Examples for Quality Risk Management in Packaging and Labeling**

**Technical Report No. 54-2**

ISBN: 978-0-939459-55-1

© 2013 Parenteral Drug Association, Inc.

All rights reserved.



## Paradigm Change in Manufacturing Operations (PCMO<sup>SM</sup>)

PDA launched the project activities related to the PCMO program in December 2008 to help implement the scientific application of the ICH Q8, Q9 and Q10 series. The PDA Board of Directors approved this program in cooperation with the Regulatory Affairs and Quality Advisory Board, and the Biotechnology Advisory Board and Science Advisory Board of PDA.

Although there are a number of acceptable pathways to address this concept, the PCMO program follows and covers the drug product lifecycle, employing the strategic theme of process robustness within the framework of the manufacturing operations. This project focuses on Pharmaceutical Quality Systems as an enabler of Quality Risk Management and Knowledge Management.


Using the Parenteral Drug Association's (PDA) membership expertise, the goal of the Paradigm Change in Manufacturing Operations Project is to drive the establishment of 'best practice' documents and /or training events in order to assist pharmaceutical manufacturers of Investigational Medicinal Products (IMPs) and commercial products in implementing the ICH guidelines on Pharmaceutical Development (ICH Q8, Q11), Quality Risk Management (ICH Q9) and Pharmaceutical Quality Systems (ICH Q10).

The PCMO program facilitates communication among the experts from industry, university and regulators as well as experts from the respective ICH Expert Working Groups and Implementation Working Group. PCMO task force members also contribute to PDA conferences and workshops on the subject.

PCMO follows the product lifecycle concept and has the following strategic intent:

- Enable an innovative environment for continual improvement of products and systems
- Integrate science and technology into manufacturing practice
- Enhance manufacturing process robustness, risk based decision making and knowledge management
- Foster communication among industry and regulatory authorities

### The Product Life Cycle



For more information, including the PCMO Dossier, and to get involved, go to [www.pda.org/pcmo](http://www.pda.org/pcmo)

# Table of Contents

<b>1.0 INTRODUCTION</b> .....	1	4.7.2 Example 02—Translation Error .....	29
1.1 Purpose and Scope.....	1	4.7.2.1 Description of Error.....	29
<b>2.0 GLOSSARY OF TERMS</b> .....	3	4.7.2.2 Risk Assessment.....	29
<b>3.0 CASE STUDY 1: CONTROL OF LIQUID DRUG PRODUCT DURING PACKAGING</b> .....	5	4.7.2.3 Risk Control .....	29
3.1 Introduction.....	5	4.7.3 Example 03—Printer Assigns and Prints Label with Incorrect Barcode.....	30
3.2 QRM Planning.....	5	4.7.3.1 Description of Error.....	30
3.2.1 Team Selection .....	5	4.7.3.2 Risk Assessment.....	30
3.2.2 Process Description.....	5	4.7.3.3 Risk Control .....	30
3.2.3 Tool Selection .....	6	4.7.4 Risk Communication and Review .....	30
3.3 Risk Assessment .....	7	<b>5.0 CASE STUDY 3: CONTROL OF LOGISTICS CHANNELS FOR LIQUID PRODUCT IN BULK HOLD PENDING PACKAGING</b> .....	31
3.3.1 Risk Identification .....	7	5.1 Purpose and Scope.....	31
3.3.2 Risk Analysis .....	8	5.2 General Discussion of Application, Benefits, Considerations.....	31
3.3.3 Risk Evaluation .....	9	5.3 Process Step/Unit Operations.....	32
3.4 Risk Control .....	9	5.3.1 Brief Description of Process Step/Unit Operations .....	32
3.4.1 High Risks and Recommended Actions ..	10	5.3.2 Process Flowchart.....	32
3.4.2 Medium Risks and Recommended Actions .....	13	5.3.3 Identify Common Risks.....	32
3.5 Risk Communication.....	13	5.4 QRM Planning.....	34
3.6 Risk Review.....	13	5.4.1 Team Selection .....	34
<b>4.0 CASE STUDY 2: RISKS ASSOCIATED WITH SECONDARY PACKAGING COMPONENTS PRODUCTION</b> .....	20	5.4.2 Tool Selection .....	34
4.1 Introduction.....	20	5.4.3 Process Description.....	34
4.2 QRM Planning.....	20	5.5 Risk Assessment.....	35
4.2.1 Team Selection .....	20	5.5.1 Risk Identification .....	35
4.2.2 Tool Selection .....	20	5.5.2 Risk Analysis and Evaluation .....	36
4.2.3 Process Description.....	20	5.6 Risk Control: Risk Reduction, Risk Acceptance .....	38
4.2.3.1 Secondary Packaging Components Production Process Flow .....	21	5.7 Risk Communication.....	39
4.3 Risk Assessment.....	23	5.8 Risk Review.....	39
4.3.1 Risk Identification .....	23	<b>6.0 CASE STUDY 4: RISKS IN PACKAGING, HANDLING AND TRANSPORT OF LIQUID FILLED GLASS SYRINGE</b> .....	40
4.3.2 Risk Analysis .....	23	6.1 Introduction .....	40
4.3.3 Risk Evaluation .....	24	6.2 QRM Planning.....	40
4.4 Risk Control .....	28	6.2.1 Product and Process Description.....	40
4.4.1 Risks and Recommended Actions .....	28	6.2.2 Tool Selection .....	42
4.5 Risk Communication.....	28	6.2.2.1 Definitions of FTA Symbols.....	42
4.6 Risk Review.....	28	6.2.2.2 Benefits of FTA .....	42
4.7 Additional Examples of Potential Failure Modes Arising from Process Substep Risks.....	28	6.2.3 Team Selection .....	42
4.7.1 Example 01—Dosing Artwork Error .....	28	6.3 Risk Overview .....	43
4.7.1.1 Description of Error.....	28	6.4 Risk Control Effectiveness Monitoring.....	45
4.7.1.2 Risk Assessment.....	29	6.5 Fault Tree Analysis .....	45
4.7.1.3 Risk Control .....	29		

<b>7.0 CASE STUDY 5: CONTROL OF LOGISTICS CHANNELS FOR REFRIGERATED BULK SOLID ORAL DOSE.....</b>	<b>46</b>
7.1 Introduction.....	46
7.2 Prerequisites: Planning, Team Selection, Product Analysis .....	46
7.3 Risk Assessment Scope and Methodology ...	47
7.4 Risk Identification.....	47
7.5 Risk Analysis.....	49
7.6 Risk Evaluation.....	50
7.7 Risk Communication.....	51
7.8 Risk Review.....	51

<b>8.0 CONCLUSION .....</b>	<b>52</b>
<b>9.0 ADDITIONAL READING.....</b>	<b>53</b>
<b>10.0 REFERENCES.....</b>	<b>54</b>

## FIGURES AND TABLES INDEX

<b>Figure 3.2.2-1</b> Process Flow Diagram for Bottling and Packaging a Liquid Product.....	6	<b>Figure 5.3.3-2</b> Absorbent Pad and Plastic Bag.....	33
<b>Table 3.3.1-1</b> Type of Hazard and Harm by Process Step .....	7	<b>Figure 5.4.3-1</b> Shipping Lane.....	34
<b>Table 3.3.2-1</b> Severity Scoring .....	8	<b>Figure 5.5.1-1</b> Process Map .....	35
<b>Table 3.3.2-2</b> Likelihood of Occurrence Scoring .....	8	<b>Table 5.5.2-1</b> Risk Evaluation and Acceptability Decision.....	36
<b>Table 3.3.3-1</b> Risk Matrix .....	9	<b>Table 5.5.2-2</b> Examples of FMEA Ratings .....	37
<b>Table 3.3.3-2</b> Risk Acceptability Decision .....	9	<b>Table 6.2.1-1</b> Product Conditions and Requirements	41
<b>Table 3.4.1-1</b> High Risks .....	11	<b>Figure 6.2.1-1</b> Process Steps .....	41
<b>Table 3.6-1</b> Risk Assessment Table.....	14	<b>Table 6.3-1</b> Risks and Recommended Actions .....	44
<b>Figure 4.2.3.1-1</b> Secondary Packaging Components Production Process Flow .....	21	<b>Figure 6.5-1</b> Case Study Fault Tree Analysis .....	45
<b>Table 4.3.2-1</b> Risk Scoring Definitions .....	23	<b>Table 7.2-1</b> Product In-transit Specifications.....	46
<b>Table 4.3.3-1</b> Risk Priority Matrix.....	24	<b>Figure 7.3-1</b> Shipping Lane Overview .....	47
<b>Table 4.3.3-2</b> Risk Assessment Table .....	25	<b>Table 7.4-1</b> Hazards Identified .....	48
<b>Figure 5.3.2-1</b> Packing: Passive System.....	32	<b>Table 7.5-1</b> Risk Scores .....	49
<b>Figure 5.3.3-1</b> Bubble Wrap and Cold Packs.....	33	<b>Figure 7.5-1</b> Threat Map of Categorized Risks.....	49
		<b>Table 7.6.1-1</b> High Risks and Recommended Actions..	50

# 1.0 Introduction

Quality Risk Management (QRM) is a systematic process for the assessment, control, communication, and review of risks. It is a mechanism of ensuring product quality is maintained throughout the product lifecycle.

An effective QRM program ensures high quality of drug product to the patient. QRM can be applied both proactively and retrospectively and should ensure that:

- the evaluation of the risk to quality is based on scientific knowledge, experience with the process, and ultimately links to the protection of the patient;
- the level of effort, formality and documentation of the quality risk management process is commensurate with the level of risk.

QRM should include systemic processes designed to coordinate, facilitate, and improve science-based decision making with respect to risk. Since the basis of any usable risk assessment is scientific knowledge and experience with the process being assessed, the evaluation of identified and analyzed risks should be defined by the risk to product quality and patient safety. Furthermore, there should be evidence for effectiveness of risk control, appropriate rationale where residual risk elements are accepted, and clear evidence that supports the decisions made.

To apply the principles of QRM, it is not always necessary or appropriate to use a formal risk assessment tool (e.g., PHA, FMEA, FTA): the use of informal risk management tools is acceptable for areas of less complexity and lower potential risk. The decision of formality in documentation should be based on each company's risk management program. The complexity of the events surrounding each decision and the potential risk involved are important inputs in determining the appropriate risk assessment methodology and corresponding level of analysis required to ensure the appropriate risk decision is made.

For the less complex and/or those decisions involving little risk, a qualitative analysis (e.g., decision tree) of the options may be all that is required. Generally, as the complexity and/or risk increases, so should the sophistication of the risk assessment tool used to facilitate the corresponding analysis.

When performing risk assessments, it is vital to use a cross-functional team so that all aspects of the process are adequately evaluated. Another critical component of this effort is to identify the key experts in the team, those who are knowledgeable in risk management principles and possess a specific set of skills in order to facilitate and lead the risk assessment sessions.

## 1.1 Purpose and Scope

PDA *Technical Report No. 54-2* is a supplemental annex to PDA *Technical Report No. 54: Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations (1)*. The technical report was distributed for peer review for comment prior to publication to ensure its suitability as a valuable guide for QRM implementation in packaging and labeling operations.

In this document, specific case studies on how to apply quality risk management (QRM) to pharmaceutical manufacturing, specifically packaging and labeling operations, are presented. Each case study highlights the different applications of QRM throughout the pharmaceutical and biotechnology manufacturing operations in packaging and labeling.

The various risk-scoring criteria in this document serve to emphasize the many uses of QRM across the industry when implementing the ICH Q9 guideline (2). They also are a reminder that there is no "one way" of using QRM.

The illustrated examples highlighted in this document of how to apply QRM tools to the packaging and labeling of products are solely based on the opinion and experience of subject-matter experts